Core Viewpoint - BillionToOne, Inc. has reiterated its full year 2025 revenue guidance of $293 million to $299 million and has initiated its full year 2026 guidance, projecting total revenue of $415 million to $430 million, indicating a growth of 40% to 45% compared to the midpoint of the 2025 guidance [1][4]. Group 1: Financial Guidance - The company expects full year 2026 revenue to be between $415 million and $430 million [4]. - This represents a growth of 40% to 45% compared to the midpoint of the full year 2025 guidance range [4]. - The company anticipates positive GAAP operating income for the full year 2026 [4]. Group 2: Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [2]. - The company utilizes a patented Quantitative Counting Templates™ (QCT™) molecular counting platform, which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [2]. Group 3: Leadership Perspective - Dr. Oguzhan Atay, Co-founder and CEO, expressed excitement about the opportunity to scale the company's differentiated platform and emphasized a clear roadmap to address significant clinical challenges [2].
BillionToOne Provides Guidance for 2026